DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Hypoxia signaling and cholesterol/steroidogenic acute regulatory protein 1 axis: interplay and role in alcohol and non-alcohol-related liver diseases
Metabolic zonation in the liver carries out the maintenance of organ and body homeostasis. Hypoxia is an inherent physiological feature of the liver and contributes to the zonal properties of the hepatic parenchyma. As a master regulator of hypoxia, the transcription factor hypoxia-inducing factor (HIF) is stabilized primarily by oxygen availability, and it is thought to contribute to steatohepatitis due to alcohol-related (ASH) and non-alcohol-related liver disease (NASH). Cholesterol has emerged as an important player in both diseases, and hypoxia increases hepatic cholesterol levels. Steroidogenic acute regulatory protein 1 (STARD1) is a mitochondrial outer membrane protein that transfers cholesterol to mitochondrial inner membrane for metabolic processing and acts as the rate-limiting step in the alternative pathway of bile acid synthesis in hepatocytes. STARD1 expression increases in ASH and NASH and determines the accumulation of cholesterol in mitochondria, which impacts the physico-chemical mitochondrial membranes properties and as a consequence impairs the activity of specific mitochondrial solute carriers, such as the 2-oxoglutarate carrier (2-OGC), limiting the exchange between cytosolic glutathione and mitochondrial 2-oxoglutarate (2-OG). Although HIF-1 is stabilized in hypoxia largely due to the requirement of prolylhydroxylases (PHDs) for oxygen to signal HIF degradation, PHDs are also dependent on 2-OG, and therefore it is conceivable that impairment of 2-OGC by STARD1-mediated cholesterol accumulation may contribute to HIF-1 stabilization due in part to decreased availability of cytosolic 2-OG. In this perspective, this review explores the interplay between HIF-1 stabilization and STARD1 induction and the potential contribution of this functional relationship to ASH and NASH., We acknowledge the support from the grants PID2019-111669RB-I00 and PID2020-115055RB-I00 from
Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de
Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California
Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the
Generalitat de Catalunya SGR-2017-1112, European Cooperation in Science & Technology (COST) ACTION
CA17112 Prospective European Drug-Induced Liver Injury Network, and the Red Nacional 2018-102799-T
de Enfermedades Metabólicas y Cáncer and the Project 201916/31 ‘Contribution of mitochondrial oxysterol
and bile acid metabolism to liver carcinogenesis’ 2019 by Fundació Marató TV3.